Arsenic pill could replace IV for rare leukemia
NCT ID NCT06882031
First seen Nov 18, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study looked at how an oral liquid form of arsenic trioxide (SDK001) works in 12 people with acute promyelocytic leukemia (APL). Researchers compared it to the standard IV version and checked if food or calcium supplements change how the drug is absorbed. The goal was to find a more convenient way to deliver this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong-Clinical Trial Centre Phase 1 Centre
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.